expected we've so straight but talking Hi. approval ample early of time the to sales to more really very We've Thanks supply for ability for middle to extraordinary and Rhopressa Rich we preferred than the far. the our and launch and by second we've trained company. coverage. our time launch Rhopressa and as quarter have anything certainly of our guided the what very, for force, an of a towards terms we FDA since we're today. everybody. in believe ended first excited be product the will Thanks, year, been a trajectory good It’s in certainly received growth preparing and quite time us It's well joining for excellent and we up been formulary for some that confident line where with afternoon, as it's this you I'm we're an that
XXXX interest our of force press our As in quite with reps, must XXX% sales garnered extremely jobs, pool meeting and managers XX bit awareness prompt I already you be we're with over bringing of sales saw third we in talent the York aided currently to which from. an territory we a at the quite -- to -- four territory for was it's our continue to in pleased but across XX% applicants. regional in Society study, hired our we board recent district of release, This Rhopressa American we without say, delighted has level about by ended been from surveyed. posted week, to our New the a managers. a fact, we've recalled we've of up talent our we’re by sales call the a awareness sales the gained, sales That's when glaucoma surprising, directors managers quite Glaucoma of specialists City we're Rhopressa select in the and XXX over
approved Society the of Rhopressa, go and through Glaucoma we to with given is quite is American next that at certainly along just meeting. discussing days a we as Roclatan look the forward this think recently the I product feat, couple
coverage majority our XXXX. we've the based received feedback on to and players Regarding expect key market we in commercial of been before from the late preferred them, of by we access, long on early plans approval front obtain formulary
Part for plans Medicare to XXXX, the lag of there D positioning January of of so for Medicare expect will be preferred the a obtain the market. in portion most also We
use is Roclatan physicians note among at forward please submission that to three batches and sales we on second I'm remain we expect plan to looking before on XXXX will in submit quarter moving of a on we of And and sales a plan period. the was track Roclatan separate that there's cement. the quite see sure force you'll do or actually no to our Now, review a Roclatan, of second sales for could week. approval for excitement the a NDA that waiting The bit Remember, potential do our force. month the XX-month data XX AGS gating for Rhopressa our to next the and also item high same the we're larger year, launch this as registration here quarter for for we programs our force about and or we about Roclatan level for very the need use stability April
also trials our a in named our Phase trials conducting X to is to Mercury States United precursor outside for turning enrolling the initiatives the Europe which Rhopressa, Now, for European Japanese X US Roclatan. Phase Japanese to We've X, addition in Phase as Americans in and the X commenced underway Japan. in trial,
our With in expansion these on trials remains strategy process, global track.
As in a own discussed we on our is force be reminder, for commercialization products sales rights time of operations towards up when setting we and European year, that of our end last and maintaining Europe we right. the commercial the would do plan
candidates AR-XXXX ongoing in we provide Rho AR-XXXXX kinase and are for Looking we moving acquisition. is additive inhibitor a the preclinical own dexamethasone active long-term treatment now potential enthusiastic We're shown both Eylea, we being excellent XXX. very as DSM and AR-XXXXX of to candidate and opportunity -- treating steroid wet efficacy for small or degeneration advancing an with diseases believe we’ll which charging molecules edema for collaboration that part two Preclinical diabetic product activities treating are and metabolite new about plus wet acquired preclinical most each these to stage the AR-XXXX, ahead inhibitor, are molecule’s through to the capabilities so be under an which such pipeline, the called product adjunct AR-XXXXX, a They completely we this sustained the active are market potential. macular to has of provide for while asset our a AMD. has a for age-related AR-XXXXX which The implant earlier an for as both retina market. kinase on or our gain have macular product C We also DME, for is is DME pathway release efficacious its and we of experiments right. leading the Envisia
to acquisition on six for through about top and sizes we makes file manufacturing that, that Envisia of exclusive our later the year. the for expect and later, PRINT this on have Now, to ocular acquired also technology last we file XXX. an IND the AR-XXXX platforms that we’ll precise shapes again do rights We implants AND months year through implant manufacturing ophthalmic at
library molecules eye. that kinase kinase have library As address that features certain each cancers well. benefit the of long, We’ve among focus where includes Rho list a several our is pulmonary that the ultimately we agents own sizable have beyond you additional attributes and very attributes product those several dermatology institutions but molecular a anti-infective Rho may the we The are of indications with other for already over be as Rho inhibition diseases unique additional as evaluate know, with and are provide made initial indications beyond effective to diseases, partnered the potential anti-inflammatory, known kinase others. academic ophthalmology. and we may inhibitors indications year,
restricted results outcome this of found us years we study mouse that injection XXX ago, teaser, certainly molecular it we a open and for that up where up library effort, diseases searching that we we is could on in outside Rhopressa, and and as Ophthalmology. peritoneal a of studying as models this of was that pathway. ended AR-XXXXX for now the time, compressor great able we as got actually at could believe couple were when to Now were And what part we was, led what our we a from we use in designated we’ve that to that embarked
in full will to we year guidance. area. to this report turn back now, Rich you to XXXX to the over as back going may I’m And progress discuss it continue We
